Breaking News, Collaborations & Alliances

MeiraGTx, Lilly Enter $475M Collaboration for Genetic Meds in Ophthalmology

Lilly gains worldwide exclusive rights to MeiraGTx AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MeiraGTx, Lilly

MeiraGTx Holdings plc, a clinical stage genetic medicines company, entered a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Co. MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbon-interacting protein-like 1 (AIPL1).  Clinical data from 11 children under the age of 4 who were born legally...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters